
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne is in a strong position to capitalize on the growing demand for liquid biopsies, with a unique technology and successful revenue growth. Their expansion into the prenatal and MRD testing markets, along with their strong operating structure and competitive pricing, gives them an advantage over their competitors. However, they will need to navigate challenges in reimbursement and competition in order to maintain their market position and continue their growth trajectory.
Bears say
BillionToOne is a molecular diagnostics company that has achieved profitability in just its 6th year of commercial launch, with a strong focus on growth initiatives. However, its revenue and profitability are highly dependent on government reimbursement and third-party payors, and the company faces competition in both the women's health and oncology markets. Additionally, its release of a new MRD test may not generate reimbursement until the end of 2027. While the company has a large untapped market and opportunities for market share gain, its closest comparables trade at an average of 10.2x 2026 EV/revenues, making it an expensive stock.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares